|
1
|
Integrated genomic analyses of ovarian carcinoma.
|
Nature
|
2011
|
47.72
|
|
2
|
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
|
Nat Med
|
2004
|
22.96
|
|
3
|
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
|
N Engl J Med
|
2003
|
16.62
|
|
4
|
Cancer immunoediting: from immunosurveillance to tumor escape.
|
Nat Immunol
|
2002
|
14.75
|
|
5
|
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
|
Proc Natl Acad Sci U S A
|
2005
|
10.89
|
|
6
|
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
|
N Engl J Med
|
2011
|
8.93
|
|
7
|
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
|
J Clin Oncol
|
2012
|
6.08
|
|
8
|
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
|
Ann Oncol
|
2014
|
4.27
|
|
9
|
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
|
Gynecol Oncol
|
2011
|
2.67
|
|
10
|
The good, the bad and the ugly - TFH cells in human health and disease.
|
Nat Rev Immunol
|
2013
|
2.33
|
|
11
|
Classification of current anticancer immunotherapies.
|
Oncotarget
|
2014
|
1.55
|
|
12
|
CANCER IMMUNOLOGY. The "cancer immunogram".
|
Science
|
2016
|
1.27
|
|
13
|
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
|
BMC Cancer
|
2013
|
0.89
|
|
14
|
Tumor infiltrating lymphocytes in ovarian cancer.
|
Cancer Biol Ther
|
2015
|
0.85
|
|
15
|
Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer.
|
Br J Cancer
|
2015
|
0.84
|
|
16
|
Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
|
Am J Pathol
|
2016
|
0.78
|
|
17
|
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
|
Nat Immunol
|
2017
|
0.75
|
|
18
|
Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer.
|
EBioMedicine
|
2017
|
0.75
|
|
19
|
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
|
JAMA Oncol
|
2017
|
0.75
|
|
20
|
Immunotherapy in ovarian cancer.
|
Ann Oncol
|
2017
|
0.75
|